347 related articles for article (PubMed ID: 31727251)
1. High-throughput discovery of cancer-targeting TCRs.
Bunse L; Green EW; Platten M
Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
[TBL] [Abstract][Full Text] [Related]
2. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity.
Zhang J; Ji Z; Smith KN
Methods Enzymol; 2019; 629():443-464. PubMed ID: 31727253
[TBL] [Abstract][Full Text] [Related]
3. TCR validation toward gene therapy for cancer.
Green EW; Bunse L; Bozza M; Sanghvi K; Platten M
Methods Enzymol; 2019; 629():419-441. PubMed ID: 31727252
[TBL] [Abstract][Full Text] [Related]
4. High-throughput sequencing of the immune repertoire in oncology: Applications for clinical diagnosis, monitoring, and immunotherapies.
Ye B; Smerin D; Gao Q; Kang C; Xiong X
Cancer Lett; 2018 Mar; 416():42-56. PubMed ID: 29247824
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers.
Zhang H; Liu L; Zhang J; Chen J; Ye J; Shukla S; Qiao J; Zhan X; Chen H; Wu CJ; Fu YX; Li B
Clin Cancer Res; 2020 Mar; 26(6):1359-1371. PubMed ID: 31831563
[TBL] [Abstract][Full Text] [Related]
6. Mapping the functional landscape of T cell receptor repertoires by single-T cell transcriptomics.
Zhang Z; Xiong D; Wang X; Liu H; Wang T
Nat Methods; 2021 Jan; 18(1):92-99. PubMed ID: 33408405
[TBL] [Abstract][Full Text] [Related]
7. T-cell Receptors for Clinical Therapy:
Kunert A; Obenaus M; Lamers CHJ; Blankenstein T; Debets R
Clin Cancer Res; 2017 Oct; 23(20):6012-6020. PubMed ID: 28645940
[TBL] [Abstract][Full Text] [Related]
8. Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.
Hammerl D; Rieder D; Martens JWM; Trajanoski Z; Debets R
Trends Immunol; 2018 Nov; 39(11):921-936. PubMed ID: 30309702
[TBL] [Abstract][Full Text] [Related]
9. An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
Chen L; Dong L; Ma Y; Wang J; Qiao D; Tian G; Wang M
BMC Immunol; 2021 Sep; 22(1):65. PubMed ID: 34583647
[TBL] [Abstract][Full Text] [Related]
10. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
11. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
13. Targeting cancer-specific mutations by T cell receptor gene therapy.
Blankenstein T; Leisegang M; Uckert W; Schreiber H
Curr Opin Immunol; 2015 Apr; 33():112-9. PubMed ID: 25728991
[TBL] [Abstract][Full Text] [Related]
14. A Framework for Annotation of Antigen Specificities in High-Throughput T-Cell Repertoire Sequencing Studies.
Pogorelyy MV; Shugay M
Front Immunol; 2019; 10():2159. PubMed ID: 31616409
[TBL] [Abstract][Full Text] [Related]
15. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
16. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
17. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
18. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
D'Ippolito E; Wagner KI; Busch DH
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171940
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
20. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
